We’ve known for a long time that Apple’s eventual goal is to be able to hide both the selfie camera and all of the Face ID components beneath the display so that the screen is completely uninterrupted ...

Across industries, pricing strategies are quietly shifting. What was once a predictable rhythm of annual increases is now giving way to continuous, incremental adjustments—and, in some cases, fully ...

FOXBOROUGH, MA. — As the New England Patriots place the finishing touches on their game plan for a Week 17 showdown against the New York Jets at MetLife Stadium, they may have the services of a highly ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

If you feel like you’re being nickel-and-dimed everywhere you shop – you probably are. Instacart has been using a shady AI algorithm that charges different prices to different customers on the same ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Scott Neustadter and Michael H. Weber have been tapped to rewrite “Dynamic Duo,” a theatrical animated film featuring Dick Grayson and Jason Todd, who have both taken up the mantle of Batman’s ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...